Page 33 of 97
Previous Page     Next Page        Smaller fonts | Larger fonts     Go back to the flash version

12-01 :: January 2012

nanotimes

Companies Facts

mer – you or me.” nanoRETE is backed by Michigan Accelerator Fund I, a Grand Rapids, Mich., USA, investment partnership focused on Michigan-based early stage life science and technology companies.

panel, is currently under FDA review. Recently, Nanosphere obtained CE-IVD Mark for regulatory approval of the full BC-GP test as an in vitro dia- gnostic in Europe.

In a single automated test, the Verigene BC-S test provides detection of Staphylococcus aureus, Staphy- lococcus epidermidis, and the mecA gene.

http://www.nanosphere.us N

Biosensor chips for use in handheld devices for detecting biohazards in the field, developed by biosystems and agri- cultural engineering professor Evangelyn Alocilja. © Kurt Stepnitz / nanoRETE

http://www.nanorete.com N gene®

anosphere, Inc. (NASDAQ: NSPH) has received 510(k) clearance from the FDA for the Veri- Staphylococcus Blood Culture Nucleic Acid

Test (BC-S). The BC-S test expands Nanosphere‘s in- fectious disease test capabilities to include the rapid detection of bacteria that cause deadly bloodstream infections. The Verigene BC-S test was submitted to the FDA as the first phase of a stepwise process to obtain clearance for a larger test panel which will be marketed as the Verigene BC-GP test. The test will be comprised of up to 16 bacterial/resistance marker targets, all on a single test cartridge. A second 510(k), needed to obtain clearance for the full BC-GP test

anostart AG (OTCQX: NASRY) has acquired two shares in its equity investment Holmenkol AG

from co-shareholder Nanogate (N7G.FSE). It now holds 50% plus one share, giving it a majority stake in Holmenkol. The transaction was approved at the Annual General Meeting of Holmenkol on December 9, 2011, and has now been carried out. Marco Beck- mann, CEO of Nanostart, commented: “Nanostart has always been convinced of the capabilities of Hol- menkol, which is why we acted quickly to exercise our preemption right.”

http://www.nanostart.de N

aturalNano (OTCBB: NNAN.OB) and Sparta Armor have entered into an exclusive Joint

Development and Supply Agreement to utilize their combined technologies. NaturalNano and Sparta Armor will develop a range of products and applica-

tions that combine their respective patented technologies to create a new class of high perfor- mance additives. These will significantly improve the mechanical properties of Sparta‘s Vehicle and Body Armor materials. Under the agreement,

33

Previous arrowPrevious Page     Next PageNext arrow        Smaller fonts | Larger fonts     Go back to the flash version
1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95  |  96  |  97